Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Freestyle Navigator, Guardian RT, and Dexcom Continuous Glucose Monitoring System Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
August 11, 2008
Byetta Preventing Mortality? Even IF True, Wrong Formulation?
Analysis of: Lilly Diabetes Drug Shows a Life-Extending Promise | www.nytimes.com
Author: GLG Expert Contributor
The recent finding that Byetta therapy decreased mortality in the ACCORD study needs to be replicated in studies designed to address that point.  Even if it is replicated and statistically significant, it probably will not be true for the widely anticipated once weekly extended formulation...
August 6, 2008
More questions than answers:
Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com
Author: GLG Expert Contributor
 Should bisphosphonates be stopped in patients who have been taking them for many years?  Should they be used at all?
June 19, 2008
Race to Market, with Competition Hot on Heels
Analysis of: After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 | newsroom.lilly.com
Author: GLG Expert Contributor
As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...
May 30, 2008
AGI-1067 May Address More than the Blood Sugar
Analysis of: AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes | www.fiercebiotech.com
Author: GLG Expert Contributor
This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome. 
April 9, 2008
PERISCOPE Makes Sense
Analysis of: New Data Showed Actos (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes | pharmalive.com
Author: GLG Expert Contributor
The recent findings regarding pioglitazone in a large, randomized, intravascular cardiac ultrasound study finally begin to show some indication of the expected efficacy for which many physicians chose to use the drug, i.e., to decrease cardiovascular disease or its progression.  From...
April 9, 2008
Slim Chance?!
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Expert Contributor
Merck's endocannabinoid inverse agonist (CB1R )recently completed a 52 wk trial in which 2000 subjects were randomized to placebo, 2, 4, or 6 mg of taranabant.  Before the trial ended, the 6 mg dosed subjects had to be rerandomized to placebo or 4 mg due to toxicity.  The...
February 11, 2008
Right data, wrong interpretation?
Analysis of: Diabetes Study Partially Halted After Deaths | www.nytimes.com
Author: GLG Expert Contributor
That more people died in the "tight" control group is true, but was it tight control that was responsible or could it have been the means by which it was controlled?  It was not rosigitazone (Avandia) or hypoglycemia responsible for the deaths, according to the articles (the scientific article...
February 4, 2008
Stay Alert for Registration Trial Results
Analysis of: Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R)) | www.pipelinereview.com
Author: GLG Expert Contributor
After the many false hopes raised using surrogate markers, we certainly want to wait for definitive end-point trial results involving fracture rate and possible long-term side effects.  However the 40% greater increase in BMD compared to the standard of bisphosphonate therapy is quite exciting. ...
January 14, 2008
Major Boon for Diabetes Companies, if only...
Analysis of: Diabetes legislation proposed | www.bizjournals.com
Author: GLG Expert Contributor
Diabesity is pandemic, too late diagnosed, too little treated.  ADA recommendations for screening with fasting blood sugars result in relatively late diagnoses since the FBS doesn't usually rise until the disease has been present for several years. 

Page : 11 to 9 of 9

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-11-21T09:45:18.197